Differentiation of regioisomeric fluoroamphetamine analogs by gas chromatography–mass spectrometry and liquid chromatography–tandem mass spectrometry
In recent years, a large number of clandestinely produced controlled-substance analogs (designer drugs) of amphetamine with high structural variety have been detected in forensic samples. Analytical differentiation of regioisomers is a significant issue in forensic drug analysis because, in most cases, legal controls are placed only on one or two of the three isomers. In this study, we used gas chromatography–mass spectrometry (GC–MS) and liquid chromatography–tandem mass spectrometry (LC–MS/MS) for the differentiation of regioisomers of fluoroamphetamine analogs (fluoroamphetamines and fluoromethamphetamines), which were synthesized in our laboratories. Free bases and their acylated and silylated derivatives were subjected to GC–MS analysis using DB-1ms, DB-5ms, and DB-17ms capillary columns. The separation of free bases was incomplete on all columns. Trifluoroacetyl derivatives of 3- and 4-positional isomers showed slight separation on DB-1ms and DB-5ms. On the other hand, trimethylsilyl derivatization enabled baseline separation of six fluoroamphetamine analogs on DB-1ms and DB-5ms columns, which was sufficient for unequivocal identification. For LC–MS/MS, a pentafluorophenyl column was able to separate six regioisomeric fluoroamphetamine analogs but a conventional C18 column could not achieve separation between 3- and 4-positional isomers. These results show that a suitable choice of derivatization and analytical columns allows the differentiation of regioisomeric fluoroamphetamine analogs.
KeywordsFluoroamphetamine analogs Regioisomer Designer drug GC–MS LC–MS
This work was supported in part by the R&D Program for Implementation of Anti-Crime and Anti-Terrorism Technologies for a Safe and Secure Society, Strategic Funds for the Promotion of Science and Technology of the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
Conflict of interest
There are no financial or other relations that could lead to a conflict of interest.
- 3.Nakajima J, Takahashi M, Seto T, Yoshida M, Kanai C, Suzuki J, Hamano T (2012) Identification and quantification of two new naphthoylindole drugs-of-abuse, (1-(5-hydroxypentyl)-1H-indol-3-yl)(naphthalene-1-yl)methanone (AM-2202) and (1-(4-pentenyl)-1H-indol-3-yl)(naphthalene-1-yl)methanone, with other synthetic cannabinoids in unregulated “herbal” products circulated in the Tokyo area. Forensic Toxicol 30:33–44CrossRefGoogle Scholar
- 4.Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2012) Identification of two new-type synthetic cannabinoids, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, CB-13(CRA-13), and AM-1248, as designer drugs in illegal products. Forensic Toxicol 30:114–125CrossRefGoogle Scholar
- 9.Europol drugs newsletter (2009) Alert 2009-001, Project SYNERGY, 4-fluoroamphetamine (EDOCF403292)1. http://ewsd.wiv-isp.be/Publicationsonnewpsychoactivesubstances/4-Fluoramphetamine/EuropolDrugsUnit_Newsletter2009-001.pdf
- 10.EMCDDA-Europol (2009) Annual report on the implementation of Council Decision 2005/387/JHA. (https://www.europol.europa.eu/sites/default/files/publications/emcdda-europol_annual_report_2009.pdf)
- 13.Seto T, Takahashi M, Nagashima M, Suzuki J, Yasuda I (2005) The identification and the aspects of the commercially available uncontrolled drugs purchased between Apr. 2003 and Mar. 2004. Ann Rep Tokyo Metr Inst P H 56:75–80 (in Japanese)Google Scholar
- 14.Nagashima M, Seto T, Takahashi M, Suzuki J, Yasuda I (2006) Spectrum data of the 3rd governor-designated drugs and the analyses of uncontrolled drugs purchased Apr. 2005–Mar. 2006. Ann Rep Tokyo Metr Inst P H 57:109–113 (in Japanese)Google Scholar
- 18.Shulgin AT, Shulgin A (1991) PIHKAL: a chemical love story. Transform Press, BerkeleyGoogle Scholar